This Article Résumé de cet Article Full Text Full Text (PDF) Submit a scholarly reply Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverman, D. G. Articles by Rinder, C. S. Search for Related Content PubMed PubMed Citation Articles by Silverman, D. G. Articles by Rinder, C. S.

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

[Le rofécoxib n’altère pas l’agrégation plaquettaire pendant l’anesthésie et la chirurgie]

From the Departments of Anesthesiology and Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticutt, USA.

Address correspondence to: Dr. David G. Silverman, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8051, USA. Phone 203-785-2802; Fax: 203-785-6664; E-mail david.silverman{at}yale.edu

Purpose: This study was undertaken because, although there is evidence that cyclooxygenase type 2 (COX)-2 inhibitors do not compromise platelets in healthy volunteers, many clinicians remain hesitant to administer them perioperatively without definitive evidence of intact platelet function during anesthesia and surgery.

Methods: In 20 patients scheduled for lower abdominal and pelvic surgery, 5 mL of blood were obtained for baseline platelet aggregometry. One hour prior to surgery, patients received an oral solution of either rofecoxib (ROF) 50 mg or placebo (PLAC) by randomized, double-blinded assignment. Approximately one hour after onset of anesthesia, an intraoperative blood sample was obtained.

Baseline and postdrug samples were centrifuged to generate platelet-rich plasma, which was challenged with adenosine diphosphate (ADP) and arachidonic acid (AA). Aggregometry was performed with and without incubation with aspirin. The data in each subject were normalized to baseline aggregation in response to AA alone and ADP alone. Intergroup differences were assessed using paired t test; P < 0.05 was considered significant.

Results: Consistent with known effects of anesthesia on platelet function, both groups had approximately 25% intraoperative declines in aggregation in response to ADP (P = NS for PLAC vs ROF) and even greater declines in response to AA (P = NS for PLAC vs ROF). Aspirin eliminated aggregation in response to AA in both groups (P = NS), and it caused similar declines in PLAC and ROF groups during exposure to ADP (P = NS).

Conclusion: This study provides strong evidence that ROF does not compromise platelet aggregation during anesthesia and surgery; nor does it interfere with the platelet inhibitory effect of aspirin.

This article has been cited by other articles:

				C.K.S. Ong, P. Lirk, C.H. Tan, and R.A. Seymour An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs Clin. Med. Res., March 1, 2007; 5(1): 19 - 34. [Abstract] [Full Text] [PDF]

				N. B. Foss and H. Kehlet Hidden blood loss after surgery for hip fracture J Bone Joint Surg Br, August 1, 2006; 88-B(8): 1053 - 1059. [Abstract] [Full Text] [PDF]

				D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF]

				R. M. Pertusi Selective Cyclooxygenase Inhibition in Pain Management J Am Osteopath Assoc, November 1, 2004; 104(11_suppl): 19S - 24S. [Abstract] [Full Text] [PDF]